Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00003681]
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00003681]
Bio2RDF identifier
NCT00003681
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003681
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Amifostine m ...... ave myelodysplastic syndrome.
brief title [clinicaltrials_vocabulary:brief-title]
Amifostine With or Without Epo ...... With Myelodysplastic Syndrome
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Compare ...... this study within 1.3 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
refractory anemia with excess blasts
refractory anemia with ringed sideroblasts
refractory anemia
secondary myelodysplastic syndromes
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2009-05-09T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003681
official title [clinicaltrials_vocabulary:official-title]
Phase II Multicenter Study of ...... k of Developing Acute Leukemia
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000066783
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
EORTC-06975
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-08-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2000-07-01T00:00:00Z
identifier
clinicaltrials:NCT00003681
title
Amifostine With or Without Epo ...... With Myelodysplastic Syndrome
@en
type
label
Amifostine With or Without Epo ...... e [clinicaltrials:NCT00003681]
@en